Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Thymosin beta-4 cycle length: what human studies ran

InvestigationalBLimited human data
Short answer: there is no established Thymosin beta-4 cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Thymosin beta-4 combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Thymosin beta-4 cycle length?
No. We found no human studies that report a treatment duration for Thymosin beta-4.
What is the longest human study of Thymosin beta-4?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Thymosin beta-4 dosing reference Full research page

References

  1. UniProtKB P62328 (TYB4_HUMAN): Thymosin beta-4 UniProt. 2026
  2. Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes J Cell Biol. 1992
  3. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair Nature. 2004
  4. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization Nature. 2007
  5. Thymosin beta 4 is dispensable for murine cardiac development and function Circ Res. 2012
  6. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers Ann N Y Acad Sci. 2010
  7. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers J Cell Mol Med. 2021
  8. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model Clin Ophthalmol. 2015
  9. Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial Cornea. 2015
  10. 0.1% RGN-259 (Thymosin beta4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial Int J Mol Sci. 2022
  11. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 (NCT03937882) ClinicalTrials.gov. 2026
  12. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-2 (NCT02974907) ClinicalTrials.gov. 2026
  13. A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction (NCT01311518) ClinicalTrials.gov. 2026
  14. Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction (NL005 phase IIb; NCT05984134) ClinicalTrials.gov. 2026
  15. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026) FDA. 2026
  16. Tractatenblad 2026 Nr. 25: Anti-doping convention (ETS No. 135), amendment to the appendix - The 2026 Prohibited List, World Anti-Doping Code (English text; entry into force 1 January 2026) Tractatenblad van het Koninkrijk der Nederlanden (official government publication). 2026
  17. openFDA Drugs@FDA query for 'thymosin' (no matching applications) FDA (openFDA Drugs@FDA). 2026
  18. PubChem compound record for thymosin beta 4 (CID 45382195) PubChem. 2026
  19. Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 (NCT05555589) ClinicalTrials.gov. 2026
  20. Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy: SEER-1 (NCT02600429) ClinicalTrials.gov. 2026